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Applications of the Wei-Lachin Multivariate One-Sided
Test for Multiple Outcomes on Possibly Different Scales
John M. Lachin*
The Biostatistics Center, The George Washington University, Rockville, Maryland, United States of America

Abstract
Many studies aim to assess whether a therapy has a beneficial effect on multiple outcomes simultaneously relative to a
control. Often the joint null hypothesis of no difference for the set of outcomes is tested using separate tests with a
correction for multiple tests, or using a multivariate T2-like MANOVA or global test. However, a more powerful test in this
case is a multivariate one-sided or one-directional test directed at detecting a simultaneous beneficial treatment effect on
each outcome, though not necessarily of the same magnitude. The Wei-Lachin test is a simple 1 df test obtained from a
simple sum of the component statistics that was originally described in the context of a multivariate rank analysis. Under
mild conditions this test provides a maximin efficient test of the null hypothesis of no difference between treatment groups
for all outcomes versus the alternative hypothesis that the experimental treatment is better than control for some or all of
the component outcomes, and not worse for any. Herein applications are described to a simultaneous test for multiple
differences in means, proportions or life-times, and combinations thereof, all on potentially different scales. The evaluation
of sample size and power for such analyses is also described. For a test of means of two outcomes with a common unit
variance and correlation 0.5, the sample size needed to provide 90% power for two separate one-sided tests at the 0.025
level is 64% greater than that needed for the single Wei-Lachin multivariate one-directional test at the 0.05 level. Thus, a
Wei-Lachin test with these operating characteristics is 39% more efficient than two separate tests. Likewise, compared to a
T2-like omnibus test on 2 df, the Wei-Lachin test is 32% more efficient. An example is provided in which the Wei-Lachin test
of multiple components has superior power to a test of a composite outcome.
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For illustration, throughout we consider the case of two
outcomes, say A and B, although all the procedures herein
generalize to $2 outcomes. We wish to test the null hypothesis H0:
(AE;AC)>(BE;BC) that the experimental therapy is equivalent to
control for both outcomes versus the alternative H1:
(AE ]AC )\(BE ]BC ) with at least one strict superiority, where
‘‘;’’ means equality for an outcome and where ‘‘]’’ means
superiority. The test against such an alternative is called a
multivariate one-directional (or one-sided) test.
Wei and Lachin [2] proposed a simple 1 df test for such a
hypothesis that was described as a test against an ordered
alternative, or a test of stochastic ordering. The test was later
studied by Lachin [3] and Frick [4,5]. Herein the application of
this test to multiple outcomes is described for a test of means, a test
of proportions, a test of event times and a test with mixed
components such as where one outcome is quantitative (using
means) and another qualitative (using proportions). For each
application, equations are also derived for evaluation of sample
size and power of the test. Multiple model-based tests are also
described. For an analysis of multiple mean differences we show
that the Wei-Lachin test is more powerful than an analysis based
on either separate tests for each outcome, multiplicity adjusted, or

Introduction
In many studies an objective is to assess whether an
experimental therapy (E) versus control (C) has beneficial effects
on multiple component outcomes. This is becoming increasingly
common in the evaluation of the comparative effectiveness of
therapies. For example, the NIDDK-funded ‘‘Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness’’
(GRADE) Study will compare four agents commonly used to
control glucose levels in type 2 (adult) diabetes [1], clinicaltrials.gov NCT01794143. The primary objective is to evaluate the
durability of glucose control over 3–6 years of treatment, the
primary outcome being the time to a confirmed rise of HbA1c (a
measure of average glucose levels) $7% (the therapeutic target
being a value ,7%) using a logrank test. A secondary outcome is
to compare each pair of treatments with respect to multiple
components of effectiveness, specifically whether one treatment is
superior to the other with respect to durability of control (eventtimes), absence of hypoglycemia over 3 years of treatment
(proportions), and a lower mean body weight at 3 years. Herein
we describe how such a test could be conducted and evaluate the
power of the test or the required sample size.
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a multivariate T2-like omnibus test. An example from a major
clinical trial is presented.
Many other tests have also been proposed, principally in the
setting of tests for differences in means. These are reviewed in the
discussion section.

"
S~

using consistent estimates of the variances and covariance, where
J~(1 1)’. Asymptotically ZS *N(0,1) under H0 from Slutsky’s
theorem. The test rejects H0 in favor of H1S when ZS §Z1{a at
level a one-sided. The above generalizes to K.2 outcomes. Note
that the test can also be obtained from the unweighted average of
the group differences relative to its standard error that provides a
convenient average measure of the group differences when all
outcomes are measured on the same scale.
Specific applications include a large sample test of means [3] or
proportions [7], a generalized linear regression model using quasi
likelihoods with a covariance matrix estimated using the information sandwich, i.e. GEE [8]; or a normal errors model for the
analysis of repeated measures [9]; or a proportional hazards model
using the information sandwich [10]; or these estimates can be
based on a distribution-free estimate such as the Mann-Whitney
difference that provides a Wilcoxon test [3,11] with the WeiLachin [2] estimate of the covariance matrix. These and other
methods allow for some observations for some outcomes in some
subjects to be missing either completely at random or at random
(conditionally).
Although often termed a multivariate one-directional (onesided) test, it is possible to conduct a two-sided one-directional test
that either E is superior to C for all components, or C is superior to
E. In that case, the Wei-Lachin 1 df test statistic is referred to the
two-sided critical value rather than the one-sided value. Herein we
describe the one-sided test.
If beneficial values of Xa are lower, but those for Xb are higher,
such as for a test of LDL and HDL, respectively, then the test
would be constructed using the negative of the values for Xb such
that db ~mEb {mCb . If higher values of both measures demonstrate
benefit for the treatment, then both da and db can be defined as
the difference of treated minus control.
This test would be appropriate when all of the outcome
measurements were on the same scale; for example, as for a test of
a beneficial effect on both systolic and diastolic blood pressure
(both mm Hg), or a test of a beneficial effect on both LDL and
HDL (both mg/dl). Other variations described below would be
appropriate for outcomes with different variances, or measures on
different scales or mixtures of different types of measures, such as
A being a quantitative variable and B being a binary variable.
An alternative approach commonly applied to test the
superiority of an experimental therapy is to base the inference
on the two separate one-sided tests. These tests would require a
correction for multiple tests such as using the Holm [12] improved
Bonferroni procedure which requires that the minimum of the two
p-values be #0.025 (one-sided) and the other #0.05 in order to
declare significance at the 0.05 level for the two tests. The
corresponding alternative hypothesis is

Let Xij designate the jth outcome variable in the ith group with
expectation E(Xij) = mij, i = E, C; j = a, b. The subscripts a, b are
used through out to refer to the two outcomes. The jth outcome
could be a quantitative measure or a binary variable (among
others). Assume that a more favorable outcome is represented by a
decreasing expectation for X. Let
ð1Þ

db ~mCb {mEb :
A positive value for each represents a beneficial effect of the
experimental therapy over control for each outcome, and a
negative value represents lack of benefit. The null and alternative
hypotheses of interest are
ð2Þ

H1S : da §0 and db §0 and sum(da ,db )w0:
Thus, H1S designates that the experimental therapy is at least as
effective as control for both outcomes and is superior to control for
either or both outcomes. This is called the multivariate onedirectional hypothesis.
In the context of an analysis of repeated measures, or
multivariate observations, Wei and Lachin [2] described a
multivariate one-directional test, what they termed a test of
stochastic ordering, i.e. a test of the null hypothesis that is directed
towards an alternative hypothesis of the form H1S in (2). Lachin
[3,6] contrasts this test with other tests, such as the omnibus test.
^ij with expectation mij. Let ^
da
Consider group-specific estimates m
^
and db designate the estimates of the difference between the
^ ~(^da ^
db )’, where
groups for each outcome as defined in (1), and D
‘‘9’’ designates the transpose. With large samples
ð3Þ

with expectation D~(da db )’ and with a covariance matrix S that
is consistently estimable with elements
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ð5Þ

 2

^ (^
^a z^
^2S ~V
da z^
db )~ s
s2b z2^
sab
s

Scale-Based Test For Multiple Outcomes

^ *N (D,S):
D

ð4Þ

b

^
^
da z^
J’D
db
,
ZS ~ pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ~
^S
s
^J
J’S

Three versions of the Wei-Lachin test are described. The first
employs the measurements using the original scale of measurement. This test, however, is not invariant to scale transformations
of the individual components. Two scale invariant tests are also
described, one based on standardized values and another based on
scale-independent Z-tests.

H0 : da ~0 and db ~0

sa b

#
sab ~Cov(^
da ,^
db )
:
db )
s2 ~V (^

The Wei-Lachin test is then provided by

Wei-Lachin Multivariate One-Directional Test and Its
Power

da ~mCa {mEa

s2a ~V (^
da )

2
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H1P : ½da w0 and=or db w0:
6 H1S :

^ J§0. That is, among the family of linear
condition that S
combinations of the estimates, the Wei-Lachin test minimizes the
loss in efficiency (power) relative to the unknown optimal linear
combination when this condition applies, in which case it is the
optimal robust linear test of H0S versus H1S. For two or more
measures with positive correlations, as would be the case under the
alternative hypothesis, Frick’s condition SJ§0 is satisfied.
When this simple condition does not apply, Frick [4] shows that
a simple weighted test is provided by

ð6Þ

However, the alternative H1P includes the case where the
experimental therapy is beneficial for one outcome but harmful for
the other, such as where da w0 and db v0 or vice versa.
Yet another possible test would be the omnibus test using a T2like test of the null hypothesis H0 versus
6 H1S :
H1O : ½da =0 and=or db =0:

^
L’D
ZS,L ~ pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
^L
L’S

ð7Þ

that is provided by
^
^ ’S
^ {1 D
XO2 ~D

ð10Þ

that is also maximin efficient where L satisfies the restriction
^ J~1. For a given S
^ , the vector L is obtained as L~B’S
^ where
L’S
^ {1 y under the
B is the quadratic program solution to miny ½y’S
constraints that yi §0 Vi and y’J~1. This test will principally be
required in cases where the null hypothesis applies, or the
treatment is inferior for some of the component outcome
measures. A SAS program for this computation is available from
the author (see Discussion).

ð8Þ

which is asymptotically distributed as chi-square on 2 (or more
generally K) df. This is likewise inappropriate because the
alternative includes cases where the experimental therapy is worse
than control for either or both outcomes.

Maximin Efficiency of the Wei-Lachin Test
For the case of two measures as herein, the restricted alternative
multivariate one-dimensional hypothesis H1S in (2) corresponds to
all points in the positive orthant of the two-dimensional parameter
space for (da ,db ). Since the test is a sum of the two estimates, the
rejection region is defined by the line of values (^da ,^db ) satisfying
ZS ~Z1{a that simply connects the points (da ,0) and (0,da ) where
^S . Thus the rejection region principally includes an
da ~Z1{a s
area of the positive orthant away from the origin, but also includes
elements of the sample space where either ^da v0 or ^db v0, but not
both. With large sample sizes, the probability of such points is
negligible for true values (da ,db ) away from zero, i.e towards the
central projection (the 45u line) of the positive orthant. Lachin [6]
provides figures to illustrate these relationships.
For a given pair of values D1 ~(da1 db1 )’ specifying a point in
the positive orthant (da1 ,db1 ), it is readily shown [13] that the
optimal likelihood ratio test of H0: D~(0 0)’ versus the point
alternative HD1 : D~D1 based on (3) is
x2LR ~

^ )2
(D’1 S{1 D
{1
D’1 S D1

Scale-based Test for Multiple Means
To illustrate the construction of the Wei-Lachin test, consider a
large sample test for a difference between groups in the means of
two outcomes where it is assumed that Xij *f (mij ,y2ij ) with some
distribution f where y2ij ~V (Xij ) is the variance of the observations
for the jth outcome in the ith group, or the residual variance after
adjusting for other covariates, and yiab ~Cov(Xia ,Xib ), i = E, C;
j = a, b. To simplify, assume that there is a common covariance
matrix in the two groups (homoscedasticity) with correlation
rab ~yab =(ya yb ). Then asymptotically
X ia
X ib

2



niab 13
nia nib A5
y2b =nib

yab

ð11Þ

where (nia, nib, niab) are the numbers in the ith group with
observed values for outcome A and B separately and jointly, i = E,
C [3].
^ ~(^
 Ca {X
 Ea ) and ^
 Cb {X
 Eb ) and D
db )’ is
db ~(X
da ^
Then ^
da ~(X
asymptotically distributed as in (3) with covariance matrix

ð9Þ

where x2LR is distributed as chi-square on 1 df under H0. Note that
x2LR is based on a weighted sum of the estimated differences
^ )~(^da ^db )’. Thus, for a given S, every point D1 ~(da1 ,db1 ) that
(D
defines a unique alternative hypothesis value in the two
dimensional parameter space entails a different optimal linear
^ . Further, the same weights are
combination of the observed D
optimal for any alternative hypothesis defined by points proportional to (da1 =sa , db1 =sb ) with the same correlation, such as the
point (cda1 =sa , cdb1 =sb ) for any c.0. This implies that the same
weights would be optimal for all points in the parameter space
falling on the vector projection defined by the specified
(da1 =sa , db1 =sb ). Thus, there are an infinite number of alternative
hypotheses corresponding to all possible projections in the positive
orthant, each with a different optimal test.
Unfortunately it is not known which projection is optimal since
the actual parameter values (da ,db ) are unknown. However, Frick
[4,5] showed that the Wei-Lachin test is maximin efficient with
respect to whichever weighted test is in fact optimal under the
PLOS ONE | www.plosone.org

0

y2a =nia
mia
*N 4
,@
niab
yab
mib
nia nib

!

2



1
1
z
nEa nCa





nEab
nCab
z
yab
6
n
n
n
nCb
Ea
Eb
Ca
6
S~ 6




4
nEab
nCab
1
1
z
z
yab
y2b
nEa nEb nCa nCb
nEb nCb
" 2
#
sa sab
:
~
sab s2b
y2a

3
7
7
7
5

ð12Þ

where the variances y2a , y2b and covariance yab can be estimated
directly from the available observations [3] under the homoscedasticity assumption. The estimated variance of the sum of mean
differences is
^ (^
^2S ~V
s
da z^
db )~^
s2a z^
s2b z2^
sab :

3

ð13Þ
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individual Z-test values of the form

These then provide the test statistic ZS in (5), or ZS,L in (10) if
Frick’s condition is not satisfied.

za zzb
ZS,z ~ pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2z2Cov(za ,zb )

Standardized Score Test for Multiple Means
For an analysis of the means of quantitative variables, the WeiLachin test ZS is not invariant to a change of scale for either of the
two measures. In cases where there is a mixture of quantitative
variables with different dispersions or units, such as LDL measured
in mg/dl and systolic blood pressure measured in mm Hg, it is
more meaningful to compute a scale-invariant test using the
average of the corresponding standardized differences. This might
also be preferred when the variances of the measures differ
substantially, even though measured on the same scale.
Let Yij denote the standardized value Yij ~Xij =yj with
V (Yij )~1. Then the standardized difference between groups for
the jth outcome is
^dYj ~Y
^ ~^dj =y
^
 Cj {Y
 Ej ~(X
 Cj {X
 Ej )=y
j
j

where zj ~^
dj =^
sj and the covariance matrix of the Z-tests (Sz ) has
^a ,d
^b )~ sab
variances V(zj )~1 ( j~a,b) and Cov(za ,zb )~Corr(d
sa sb
with elements from (12). If nia ~nib ~niab for i~E,C then
Cov(za ,zb )~rab .
Under the alternative hypothesis where the components f^
dj g or
fzj g are expected to be positive, then the covariance will likewise
be expected to be positive and Frick’s condition Sz J§0 is readily
satisfied. If this condition is not be satisfied, we would use the test
^ and S
^ z in lieu of D
^ in (10).
ZS,L using Z~(za zb )’ and S
It should be noted that this Z-based test is analogous to the
Gastwirth [14] miximin efficient robust test (MERT) that is a
obtained using the sum of the extreme Z-tests from a set of tests
against a closed family of alternatives. For a family with only 2
alternatives (or tests), the MERT is equivalent to the above Zbased test.

ð14Þ

^ Y ~(^dYa ^dYb )’ is asymptotically normally distributed with
where D
expectation (da =ya db =yb )’ and covariance matrix

3
1
1
nEab
nCab
z
rab
z
6
nEa nCa
nEa nEb nCa nCb 7
7:

SY ~6
5
4  nEab
nCab
1
1
rab
z
z
nEa nEb nCa nCb
nEb nCb

Comparison of the Tests for Means

2

^ ~y
^ ), it can readily be shown
When the variances are equal (y
a
b
that the standardized scores test equals the scale-based test
(ZS ~ZS,Y ) regardless of the sample sizes or sample fractions.
When the group sample sizes are equal with no missing values, it
can also be shown that the standardized scores test equals the Zbased test (ZS,Y ~ZS,Z ). When both the variances and sample
sizes are equal, then all three tests are equal.
Direct computation of the three tests (ZS , ZS,Y , ZS,z ) over a
range of sample sizes, variances and group differences shows that
 S,Y 1:032
 S , i.e. with given proportionalities. Thus,
 S,z 1:009
w Z
w Z
Z
and
ZS,z
are
virtually
equivalent
with
ZS,Y
corr(ZS,Y ,ZS,z )~0:988 over the range of alternatives considered.
These two tests are about 3% greater than the scale-based test with
respective correlations of 0.977 and 0.953. Thus, on this basis the
standardized scores or Z-based test would appear to be preferable.

ð15Þ

The resulting standardized Wei-Lachin test is then provided by
^da =y
^Y
^ z^db =y
^
J’D
a
b
ZS,Y ~ pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ~
^
s
^
S,Y
J’SY J

ð16Þ


 

1
1
1
1
z
z
z
z
s2S,Y ~
nEa nCa
nEb nCb


nEab
nCab
z
2rab
nEa nEb nCa nCb

ð17Þ

where

General Expressions for Power and Sample Size for the
Tests
For each variation of the test, expressions for the evaluation of
sample size and power are readily obtained. Under H1S with
da z^
db ) that may be a function
specified values (da ,db ), let s2S ~V (^
of (da ,db ) depending on the underlying model. Also, let s2S ~w2S =N
represent the factorization of this variance into a term w2S and N.
Therefore, from standard equations [15], the power of the test to
reject H1S for specified values (da ,db ) is provided by
1{b~W(Z1{b ) where

that is consistently estimated from the estimate of the correlation
^ ~y
^ ), then
^ ab . When the variances of the outcomes are equal (y
r
a
b
ZS,Y ~ZS . With equal sample sizes and no missing values,
nia ~nib ~niab ~n~N=2, (i~E,C), then
i
pﬃﬃﬃﬃﬃh
^ z^db =y
^
N ^da =y
a
b
pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
:
ZS,Y ~
8(1z^
rab )

ð18Þ

Z1{b ~

As above, with positive correlations, Frick’s condition SY J§0 is
satisfied. If not, then the weighted test is provided by ZS,L using
^ ^db =y
^ )’ and S
^ Y ~(^da =y
^ Y in (10).
D
a
b

pﬃﬃﬃﬃﬃ
N (da zdb )
{Z1{a
wS

ð20Þ

and where the variance s2S is factored as

Z-Based Test
In some cases, it may be desired to conduct a test with mixtures
of quantitative and qualitative outcomes (or other types), e.g.
combining tests for means, proportions and/or life-times. In such
cases a multivariate one-directional test with respect to the
multiple outcomes can be obtained from a combination of the
PLOS ONE | www.plosone.org

ð19Þ

s2S ~

"
#
w2S
w2 zw2b z2wab
~ a
N
N

ð21Þ

and the individual variances and the covariance are factored as
s2a ~w2a =N, s2b ~w2b =N, and sab ~wab =N. Specific expressions are
4
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presented below. Conversely, the sample size required to provide
power 12b to detect specified values (da ,db ) is provided by


(Z1{a zZ1{b )wS 2
N~
:
da zdb

2
6
6
V~6
4

ð22Þ

"
~

To evaluate these equations, is it necessary to provide the
components of w2S , i.e. (w2a , w2b , wab ), and to specify the values
(da ,db ) representing the minimal degree of superiority of treatment
both outcomes of clinical interest.
For the standardized scores test in (16) the variance is likewise
factored as s2S,Y ~w2S,Y =N. Then power is obtained from

Z1{b ~

pﬃﬃﬃﬃﬃ
N ðda =ya zdb =yb Þ
{Z1{a
wS,Y

y2a

yab



1
1
z
jEa jCa



jEab
j
z Cab
jEa jEb jCa jCb
#

w2a

wab

wab

w2b


yab


jEab
j
z Cab
jEa jEb jCa jCb


1
1
z
y2b
jEb jCb

3
7
7
7
5

ð27Þ

and s2S ~w2S =N where
"

y2a ðjEa zjCa Þ y2b (jEb zjCb )
z
z
jEa jCa
jEb jCb


jEab
j
z Cab
:
2yab
jEa jEb jCa jCb

w2S ~

ð23Þ

ð28Þ

and the required sample size from


(Z1{a zZ1{b )wS,Y 2
N~
:
da =ya zdb =yb

When the groups are of equal size with the same fractions
observed (jia jib jiab )~(ja jb jab ) for i~E,C, then
ð24Þ

"
w2S ~2

Likewise, for the Z-based test in (19), power is obtained from
pﬃﬃﬃﬃﬃ
N ðda =wa zdb =wb Þ
ﬃ {Z1{a
Z1{b ~ qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2z2Corr(^da ,^db )

ð29Þ

When there are equal-sized groups with no missing observations
then ja ~jb ~jab ~0:5 and

ð25Þ



w2S ~4 y2a zy2b z2yab :

and the required sample size from
qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ32
2
(Z1{a zZ1{b ) 2z2Corr(^da ,^db )
5
N~4
da =wa zdb =wb


#
y2a y2b
2yab jab
z z
ja
jb
ja jb

ð30Þ

Then the power or sample size required to detect specified
values da and db are provided by (20) or (22), respectively.
For example, suppose we desire to test the treatment group
differences in both systolic (A) and diastolic (B) blood pressures,
lower values of each being better. From existing data the
respective SDs are ya ~13 mm Hg and yb ~7 mm Hg. The
correlation of the two is rab ~0:6 which yields
yab ~(0:6)(13)(7)~54:6: Assume that we wish to detect a
treatment group difference equal to 0.25 SD for each measure,
so that da ~(0:25)(13)~3:25 and db ~(0:25)(7)~1:75: For equalsized groups with no missing observations then ja ~jb ~jab ~0:5
and w2S ~4½132 z72 z2(54:6)~1308:8. For a one-sided test at the
0.05 level, the sample size required to provide power of at least 0.9
is provided by

ð26Þ

where Corr(^da ,^db )~wab =(wa wb ). Expressions for the correlation
are provided below for specific cases.
Also, each of the above expressions for power can be expressed
as E(Z)~Z1{a zZ1{b where E(Z) is also termed the noncentrality parameter of the test. Thus, the first term on the right
hand side of (20), (23) and (25) is the respective expression for E(Z).

Sample Size and Power for Tests for Means
To assess sample size and power for a test, let E(nia nib
niab )~N(jia jib jiab ) denote the expected numbers observed in
the ith group, where N is the total sample size in the two groups
with at least one observed measurement (not including any subject
missing both A and B measurements).

"
pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ#2
(1:645z1:282) 1308:8
~448:52
N~
3:25z1:75

The Scale-Based Test

ð31Þ

or 225 subjects per group (rounded up). From equation (20), with
this sample size the power to detect smaller differences of 0.2 SD
with da ~2:6 and db ~1:4, then the power using N = 450 is
provided by

From (12), the covariance matrix Cov(^da ^db ) can be factored as
S~V=N where

"pﬃﬃﬃﬃﬃﬃﬃﬃ
#
450(2:6z1:4)
pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Z1{b ~
{1:645 ~0:700
1308:8

ð32Þ

with power W(0:7)~0:758. Below we also examine the power for
this example using the other tests.
PLOS ONE | www.plosone.org
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using the Bonferroni correction for 2 one-sided tests. To simplify,
assume that the differences of interest are a common fraction v of
the standard deviations, i.e. da ~nya and db ~nyb in which case

The Test Using Standardized Means or Z-Scores
When the component measurements have different units or
scales of measurement, then either the test based on the
standardized values or the individual Z-tests is invariant to scale
transformations, and, therefore, preferred. This test may also be
preferred when the component measures have different variances,
even when measured on the same scale.
For the standardized-scores test, from (16),
ðj zjCa Þ (jEb zjCb )
z
z2rab
w2S,y ~ Ea
jEa jCa
jEb jCb



2(Z1{a=2 zZ1{b ) 2
NP ~
n

Let NS denote the total sample size required for the Wei-Lachin
test as obtained from (22) with the value w2S that is obtained from
(30) to yield




jEab
j
z Cab : ð33Þ
jEa jEb jCa jCb




(Z1{a zZ1{b ) 2  2
4 ya zy2b z2yab
NS ~
da zdb



(Z1{a zZ1{b ) 2  2
4 ya zy2b z2yab :
~
n½ya zyb 

When there are equal-sized groups with no missing observations
(all fjg~0:5) then w2S,Y ~8(1zrab ). Power and sample size are
then obtained from (23) and (24).
For the above example, with equal sample sizes and no missing
db )~corr(Xa ,Xb )~rab ~0:6. Since the differdata, then corr(^da ,^
ence is specified as a fraction of the standard deviation,
da ~(0:25)ya and db ~(0:25)yb , then da =ya ~db =yb ~0:25 and
the required sample size is
"
pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ#2
(1:645z1:282) 8(1z0:6)
N~
~438:65
2(0:25)

#

2 "
2 Z1{a=2 zZ1{b
NP
ðn½y zy Þ2
~
 2 a 2 b

NS
Z1{a zZ1{b
4n2 ya zyb z2yab
"
#

2 2
Z1{a=2 zZ1{b
ya zy2b z2ya yb
~
Z1{a zZ1{b
y2a zy2b z2yab

ð34Þ

ð39Þ

Since Z1{a=2 wZ1{a and ya yb §yab , then NP wNS .
For example, consider a one-sided test at the 0.05 level (0.025
adjusted for two tests) with 90% power to detect an improvement
E versus C at any level v. Assume a correlation among the A and B
measures of 0.5 and variances y2a ~y2b = 1. Then the ratio of
sample sizes is

Relative Efficiency Versus Other Tests
It is also instructive to compare the efficiency of the Wei-Lachin
test versus two one-sided tests or an omnibus test. We do so here in
the context of a test for means, and these results apply in general to
other tests as well. Standard methods for the evaluation of the
asymptotic relative (Pitman) efficiency (ARE) of two tests under a
local alternative would not account for the necessary adjustment to
the significance level for two tests. However, the ARE can be
interpreted as the ratio of sample sizes needed to provide the same
level of power for a specific alternative. This ratio of sample sizes
can be derived directly from (22) relative to the like expression for
either two separate tests or the omnibus test.
Pairwise Tests. Consider the power of the test for means
with equal group sample sizes and residual variance y2j for the jth
outcome where each is measured on the same scale so that the
original scale-based test is appropriate. For a given alternative
(da w0,db w0). For two tests with equal-sized groups, each being
of size N/2, with no missing data (jia ~jib ~jiab ~1=2), the
variance of the difference for the jth outcome is


 

NP
1:96z1:282 2
4
~1:64
~
1:645z1:282 2z2(0:5)
NS

ð40Þ

which indicates that two separate tests requires a 64% greater
sample size than does the Wei-Lachin test for this a and b, or that
the Wei-Lachin test is 39% more efficient. These results apply
approximately to other tests such as the test for proportions or the
test of life-times.
The Omnibus MANOVA Test. Similarly, the omnibus
multivariate analysis of variance (MANOVA) T2-like test of H0
versus the general alternative H1O in (7) is provided by
^ {1 (^
X 2 ~(^
da ^
da ^
db )S
db )’ that is asymptotically distributed as chisquare on 2 df. The corresponding non-centrality parameter is
h2 ~(da db )S{1 (da db )’

ð35Þ

~(nya nyb )S{1 (nya nyb )’

assuming homoscedasticity. Then the equivalent expression for the
total sample size required based on the separate tests is provided
by

ð41Þ

where the inverse covariance matrix is

(
 
)
(Z1{a=2zZ1{b )2ya 2 (Z1{a=2zZ1{b )2yb 2
ð36Þ
,
NP ~max
da
db
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ð38Þ

Thus, the ratio of sample sizes needed with the two-pairwise
one-sided tests versus the Wei-Lachin test is

that is slightly less than the N required for the scale-based test.
This indicates that for this example, the test based on standardized
scores would have greater power for a given N.
The same numerical result also is obtained using the Z-based
test since in this case the two tests are equal.

V (^dj )~4y2j =N

ð37Þ

S{1 ~

6

N
4 y2a y2b {y2ab

"

y2b
{yab

#
{yab
:
y2a

ð42Þ
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Thus
"

h2 ~

NO n2 y2a y2b {ya yb yab
2
y2a y2b {y2ab

"

#

S~
~NO w2 :

ð43Þ

NO ~h2 (a,b,df )=w2

ð12:654Þð2Þ(y2a y2b {y2ab )
:
n2 y2a y2b {ya yb yab

~

y nCab
Eab nEab
z Cab
nEa nEb
nCa nCb

3
yEab nEab yCab nCab
z
nEa nEb
nCa nCb 7
7
7
2
5
yEb y2Cb
z
nEb
nCb

ð48Þ

that is consistently estimable from the sample quantities [7]. Then
the statistic ZS is constructed as in (5) based on the sample estimate
of the variance s2S as in (13). Note that in this case, since all
measures are based on Bernoulli variables, there is no advantage
to using the test based on standardized scores. Alternately, the
Z-based test would be constructed as in (19) with
d ^
^b ).
Corr(
Corr
da ,^
db )~^
sab =(^
sa s
For the assessment of sample size or power the covariance
would be factored as S~V=N with terms (w2a ,w2b ,w2ab ) and where
db )~wab =(wa wb ).
Corr(^
da ,^
For example, assume that the outcomes in the control group are
expected to have probabilities pCa ~pCb ~0:4 with joint probability pCab ~0:2 and that the respective probabilities in the
experimental group are pEa ~pEb ~0:3 with joint probability
pEab ~0:15. Then y2Ea ~y2Eb ~(0:3)(0:7), y2Ca ~y2Cb ~(0:4)(0:6),
yEab ~(0:15{0:32 ), and yCab ~(0:20{0:42 ). With equal sized
groups and no missing observations, then jia ~jib ~jiab ~1=2
(i~E,C) and

ð44Þ

ð45Þ

Then, for the above example, the inverse efficiency relative to
the Wei-Lachin test is provided by the ratio of NO to NS in (38) to
yield
ð12:654Þð2Þ(1{0:25)
NO
ð1{0:5Þ
~
~1:477

NS
1:645z1:282 2
(12)
2

#

y2Ea y2Ca
z
nEa
nCa

6
6
6
4y

For the above example, h2 (0:05,0:10,2)~12:654 and

NO ~

sab s2b

2

The non-centrality parameter for a test at level a on K df that
provides power 12b, designated as h2 (a,b,K), is readily obtained,
such as from the SAS function CNONCT. Then the required
sample size is provided by

s2a sab

ð46Þ

w2s ~
ð49Þ


4 (0:3)(0:7)z(0:4)(0:6)z(0:15{0:32 )z(0:20{0:42 ) ~2:20

and the Wei-Lachin test is 32% more efficient for these operating
characteristics. If the computation is conducted for a two-sized
Wei-Lachin test, then NO/NS = 1.204 and the Wei-Lachin test is
17% more efficient.

with the resulting computation
"
pﬃﬃﬃﬃﬃﬃﬃ#2
(1:645z1:282) 2:2
~471:2:
N~
2(0:1)

Power of Tests for Multiple Proportions, and
Mixtures of Proportions and Means

ð50Þ

Test for Multiple Proportions
Now consider a large sample test for a difference between
groups in the probabilities (pij ) of two Bernoulli variables Xa and
Xb where the corresponding sample proportions are distributed as
pij *N(pij ,y2ij =nij ) with Bernoulli variance y2ij ~pij (1{pij ) for the
jth outcome within the ith group and sample sizes nij ~Njij ,
i~E,C; j~a,b: The covariance of the Bernoulli variables within
the ith group, Cov(Xia ,Xib ), is simply
yiab ~E(Xia Xib ){E(Xia )E(Xib )~piab {pia pib

The correlation of the estimates is
pﬃﬃﬃ
2ðyEab zyCab Þ
qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
db )~ qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Corr(^
da ,^
2
yEa zy2Ca z y2Eb zy2Cb
ð51Þ
pﬃﬃﬃ

2 (0:15{0:32 )z(0:20{0:42 )
pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
~
~0:10541:
2 (0:3)(0:7)z(0:4)(0:6)

ð47Þ
Then the test based on Z-test values would require

where piab is the probability that both variables are positive [7].
Again we assume that a lower probability is better. If not, the (0, 1)
categories should be reversed.
^ ~(^
da ^
db )’ is
Then ^da ~( pCa {pEa ) and ^db ~( pCb {pEb ) and D
asymptotically distributed as in (3) with expectation D~(da db )’
where dj ~(pCj {pEj ) and with covariance matrix

2

32
p
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
6(1:645z1:282) 2z0:105417
6
7
N~6
7 ~405:85:
0:1
4
5
2 pﬃﬃﬃpﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2 (0:3)(0:7)z(0:4)(0:6)

ð52Þ

Thus, the Z-based test is again more efficient than the scalebased test.
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Tests for Means and Proportions

"

pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ#2
(1:645z1:282) 1640:9
N~
~540:5:
5:1

Scale-Based Test. It is also possible to determine the joint
distribution of a test for means of one outcome and a test for
proportions of another. Let XA denote a quantitative measurement with means mia and variance y2a , assuming homoscedasticity,
and Xib denote a binary variable with probability pib and variance
y2ib ~pib (1{pib ) in the ith group (i~E,C). The covariance of the
two in the ith group is provided by

yiab ~Cov(Xia ,Xib )~E(Xia Xib ){E(Xia )E(Xib )

Z-Based Test. Alternately, since the scale-based test is not
invariant under transformations, it would be more appropriate to
employ a combination of the Z-tests. In this case,

da
~
wa

ð53Þ

~pib (mia(1) {mia )

where mia(1) ~E(Xia DXib ~1) is the mean of the quantitative
variable Xia among those where the binary
 variable Xib ~1. Then
1
1
2
2
^


, assuming
da ~(XCa {XEa ) with variance sa ~ya
z
nEa nCa
^db ~( pCb {pEb )
with
variance
homoscedasticity,
and
2
2
2
sb ~yEb =nEb zyCb =nCb . The covariance is

Cov(XEa ,XEb )nEab Cov(XCa ,XCb )nCab
z
nEa nEb
nCa nCb

~

yEab nEab yCab nCab
z
:
nEa nEb
nCa nCb

Eb

V~

w2a wab
2
wab wb

#

"
~

4y2a

2(yEab zyCab )

yEab jEab yCab jCab
z
jEa jEb
jCa jCb
ﬃ
rﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃsﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
1 y2Eb y2Cb
ya
z
z
jEa jCa jEb
jCb

ð54Þ

da
da
~
;
wa 2ya
db
pCb {pEb
pCb {pEb
~ qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ~ pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ;
wb
2pEb (1{pEb )z2pCb (1{pCb )
2y2Eb z2y2Cb
Cov(Za ,Zb )~

ð58Þ

2(yEab zyCab )
qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ :
2ya 2(y2Eb zy2Cb )

Then for this example
da
5
~0:125;
~
wa 2(20)

Cov(Za ,Zb )~

db
0:1
~ pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ~0:1054
wb
2½0:24z0:21

2(20)

ð59Þ

2(3z7)
pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ~0:5271
2(0:24z0:21)

and
ð55Þ
"

pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ#2
(1:645z1:282) 2z2(0:5271)
~492:9:
N~
0:125z0:1054

and s2S ~1600:9z2(20)~1640:9. Thus, the required sample size
for a one-sided test at the 0.05 level and 90% power is provided by
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ð57Þ

When there are equal sample sizes between groups with no
missing data for either measure then

#

2
2
2(yEab zyCab ) 2(yEb zyCb )
"
#
#
1600 20
2(3z7)
4(20)2
~
~
20 0:9
2(3z7) 2½0:24z0:21

"

Cb

w
da b
db )~ ab ~
Cov(Za ,Zb )~Corr(b
wa wb

To conduct the test these variances and covariances can be
estimated consistently from the corresponding sample estimates.
Sample size and power can then be evaluated as above.
For example, assume that we wish to test the difference between
groups in the mean level of LDL and the prevalence of
hypertension. Assume a SD ya ~20 in both groups and that the
difference of interest is da ~5 that corresponds to a 0.25 SD
difference. While it is not necessary to specify the actual mean
values within each group to compute da , it is necessary to compute
the covariance. Within each group assume that the overall mean
values are mEa ~170 and mCa ~175 (corresponding to da ~5), and
a greater treatment effect among those who are hypertensive with
mean values mEa(1) ~175 and mCa(1) ~185. Assume that the
probabilities of being hypertensive are pEb ~0:60 and
pCb ~0:70, yielding db ~0:1. Then the variance components are
y2Eb ~(0:6)(0:4)~0:24,
y2Cb ~(0:7)(0:3)~0:21,
yEab ~(0:6)(175{170)~3:0, and yCab ~(0:7)(185{175)~7.
Assuming equal sized groups with no missing data, then
^
D~(^da ^db )’ is asymptotically normally distributed with covariance
matrix S~V=N and
"

da
rﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ;
1
1
ya
z
jEa jCa

db
db
pCb {pEb
~ sﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ~ rﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
wb
2
2
p
(1{p
pCb (1{pCb )
Eb
Eb )
yEb yCb
z
z
j
jCb
Eb
j
j

 Ea ,pEa )zCov(X
 Ca ,pCb )
sab ~Cov(^da ^db )~Cov(X
~

ð56Þ

ð60Þ

Thus, the Z-based test would provide greater power in this case.
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Note that the Xijk are non-iid Bernoulli variables with event
probabilities that are a function of the underlying hazard rates for
the event and losses to follow-up and the period of exposure Uijk.
Within each group, for each outcome assume a constant hazard
lij ~Dij =Tij . Let E(Dij )
rate lij that is consistently estimated as ^
designate the expected number of events based on the assumed
hazard rate lij , sample size, periods of recruitment and follow-up,
and losses-to follow-up in that group. Asymptotically,

Power of Tests for Multiple Event-Times
Tests for Multiple Event-times
For right censored event time data, a member of the family of
Aalen-Gill tests [16,17], also known as the G r family of tests of
Harrington and Fleming [18], can be used to test the hypothesis of
equal hazard functions, or survival functions, between two groups.
This family includes the logrank test that is asymptotically fully
efficient under a proportional hazards model and is equivalent to
the score test of the unadjusted group effect in a Cox Proportional
Hazards model. It also includes the Peto-Peto-Prentice modified
Wilcoxon test that is optimal under a survival proportional odds
model. Andersen, Borgan, Gill and Keiding [19] describe a
generalization of the tests for K.2 groups. These tests are
equivalent to the family of weighted Mantel-Haenszel statistics
described by Kalbfleisch and Prentice [20].
Wei and Lachin [2] describe a multivariate rank test for event
times that is a generalization of the above families of tests to the
case of multiple time-to-event outcomes. They also introduced the
one-directional multivariate test described herein, what they
termed the test of stochastic ordering, to assess whether the
treatment group event times differed in a favorable direction for all
of the outcomes. A SAS macro for these computations is available
(see discussion). The computational details will not be provided
herein.
Lakatos [21] presents a general approach to the evaluation of
sample size and power for the Mantel-logrank test that allows for
time varying hazard rates, proportional or non-proportional
hazards, and other design features. When the hazard rates are
assumed constant over time with a constant of proportionality, a
simple exponential model applies in which case the methods of
Rubenstein et al. [22] or Lachin and Foulkes [23] can be applied.
Herein we describe the computation of sample size or power for
the Wei-Lachin test for multiple event-time outcomes under the
exponential model of Lachin and Foulkes that includes a
generalization of the method described by Lachin [15] based on
the difference in the exponential hazard rates. Freedman [24]
showed that the latter expression can also be derived from the
expected value of the logrank chi-square test value under a
proportional hazards model. Lachin and Foulkes [23] also show
that the power of the test based on the difference in the estimated
hazards is virtually identical to that for a test based on the log
hazard ratio.
We assume that there are two or more outcome events where no
one outcome is a competing risk for the other outcomes, such as
the time to development of diabetic retinopathy and time to
developing diabetic nephropathy, neither of which is fatal. Let
Xijk = 1 denote that the kth subject had the jth event in the ith
group at time tijk, and Xijk = 0 denote right censoring at time Uijk
that in turn is the minimum of the loss to follow-up time and the
administrative censoring time for those who remain free of the jth
outcome, i = E, C; j = a, b. Then the total number of subjects with
an event (called events) (Dij) and total time at risk (Tij) for the ith
group and the jth outcome are
Dij ~

Tij ~

X
k

Xijk

^
lij *N (lij ,u2ij )

where u2ij ~l2ij =E(Dij ) that is consistently estimated as ^u2ij ~^
l2ij =Dij .
^ ~(^
lCa {^
lEa ), ^
db ~(^
lCb {^
lEb ) and, D
da ^
db )’ is
Then ^
da ~(^
asymptotically distributed as in (3) with expectations
da ~(lCa {lEa ) and db ~(lCb {lEb ) and covariance matrix S
^ will
db ). A test based on D
db ) and Cov(^
da ^
with elements V (^
da ),V (^
have power approximately equal to that of the Wei-Lachin
multivariate one-directional test using the Wei-Lachin bivariate
Aalen-Gill logrank test under proportional hazards. Thus, we
describe the power of the bivariate logrank test based on the test of
the difference in exponential hazards. Then the scale-based test
employs
s2S ~V (^
da )zV (^
db ){2Cov(^
da ^
db )
"
V (^
dj )~u2Ej zu2Cj ~

ð63Þ

#
l2Ej
l2Cj
z
E(DEj ) E(DCj )

that is consistently estimated using ^
lij and the observed Dij ,
j~a,b.
File S1 shows that the covariance is expressed as
E ½DEab {E ½DEabI  E ½DCab {E ½DCabI 
z
db )~
Cov(^
da ^
E ½TEa E ½TEb 
E ½TCa E ½TCb 

ð64Þ

where Diab is the number of subjects who experience both the A
and B events and E ½DiabI  is the expected number with both
events under the assumption that the Bernoulli variables Xiak and
Xibk are independent. Each is consistently estimated from the
observed numbers of events and total time at risk. The
computational expression for DiabI is also presented in File S1.
The resulting test as in (5) then is based on the variance estimate
^
^
^
^
l2Ea
l2
l2
l2
z Ca z Eb z Cb {
DEa DCa DEb DCb


DEab {DEabI DCab {DCabI
2
z
TEa TEb
TCa TCb
^2S ~
s

ð65Þ

that is solely a function of the numbers of individual and joint
events, the corresponding event times and the corresponding times
of at risk. Accordingly, the power of the test is a function of the
expected numbers of events and expected time at risk that in turn
are a function of the design parameters and sample size.
Lachin and Foulkes [23] provide the expression for the
probabilities of events fpij g for given hazard rates for events
flij g and losses to follow-up fgij g, recruitment period R with
recruitment shape parameter c and total follow-up Q, and sample
size nij ~Njij . Then the expected number of events is obtained as

ð61Þ

X 

Xijk tijk z(1{Xijk )Uijk :
k
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s2b ~12:1E–4,
and
sab ~1:43E–4,
that
provides
db )~0:147 and s2S ~22:7E–4. Substituting into (20),
corr(^
da ,^
yields Z1{b ~1:292 and power = 0.902.
A similar computation using (25) shows that an n of 197 per
group would provide power = 0.885 using the Z-based test,
indicating that in this setting the Z-based test would have less
power than the original scale based test.

E(Dij )~Njij pij and likewise the expected period at risk as
E(Tij )~Njij tij . File S1 also provides expressions for E(Diab ),
E(DiabI ) and E(Tij ). Then s2S ~w2S =N where
l2Ea
l2
l2
l2
z Ca z Eb z Cb
jEa pEa jCa pCa jEb pEb jCb pCb
ð66Þ


j ½pEab {pEabI  jCab ½pCab {pCabI 
{2 Eab
z
:
jEa tEa jEb tEb
jCa tCa jCb tCb

w2S ~w2a zw2b {2wab ~

Generalizations
It is also possible to obtain a test based on the combination of
group differences in hazard rates and differences in proportions or
means. As in the preceding sections this requires the derivation of
the covariance of the measures within each treatment group.
Alternately, a multivariate one-directional test can be obtained
using multiple regression models as now described.

Power and sample size are then obtained from (20) and (22).
However, to obtain an analytic solution to these equations, a
specific model must be specified for the dependence of the eventtimes with a given correlation, such as the Marshall and Olkin [25]
bivariate exponential model. Hougaard [26] provides a review of
such models. Alternately, a simulation model could be implemented using a given bivariate exponential distribution. Herein, a
simpler approach is described using a shared frailty.
Assume that the two event types share a common frailty with
parameter liF . Then in the simulation model, in the ith group,
three random exponential times are generated as

Model-Based Analysis of Multiple Outcomes
The preceding sections describe the application of the WeiLachin test to a combination of the group differences in means or
proportions or hazard rates. In each case the covariance of the
group differences, or of the corresponding Z-values, is described.
The test statistic can then be computed using a consistent sample
estimate of the variances and covariance(s), and the expression for
power can be obtained using specified values for these parameters.
In principle it is possible to construct a test for combinations of
other types of outcomes, such as the difference in rates (counts) of
events under a Poisson model, and to derive the equations to assess
the power of the tests. However, it is more convenient to provide
model-based generalizations of this approach.
From basic principles, Pipper, Ritz and Bisgaard [27] describe
the joint distribution of parameter estimates from multiple models,
not necessarily all of the same type. Consider two models for each
of two outcomes, each with Kj parameters and coefficient
hj1 . . . ^
hjKj )’. Arbitrarily, assume that the first
estimates ^
hj ~(^
^
parameter estimate hj1 represents the difference between groups

t1 *exponential(lia {liF )

t2 *exponential(lib {liF )

t3 *exponential(liF )
and the correlated exponential event times are then obtained as
tia ~min(t1 ,t3 )*exponential(lia )

on some scale, no difference represented by a value of zero, and
the remaining Kj estimates represent the intercept (if any) and
h
i’
other covariate effects. Then U‘j (^
hj )~ U‘j1 (^
hj ) . . . U‘jKj (^
hj ) is

tib ~min(t2 ,t3 )*exponential(lib ):
from which the probability piab of both events can be obtained.
For example, consider a Q~5 year study with linear (constant)
recruitment over a R~3 year interval allowing for a loss-to-followup hazard rate of 0.05 per year and with equal size groups. Within
the control group assume that the hazard rates are lCa ~0:2=year
and lCb ~0:3=year and that the experimental therapy yields risk
reductions of RRa ~0:8 and RRb ~2=3, or hazard rates of
lEa ~0:16=y and lEb ~0:2=y so that da ~0:04 and db ~0:10. To
allow for a correlation of the event times we assume shared frailties
of lEF ~0:08 and lCF ~0:1: For a given sample size, the
simulation model (herein with 10,000 replications) provides direct
computation (within a small degree of error) of the expected
quantities (E(Dij ), etc.) from which power is computed. By a
simple search it was found that a n of 197 per group provides a
one-sided one-directional test with 90% power.
For this sample size, the expected number of events marginally
are E(DCa )~90:3, E(DCb )~116:9, E(DEa )~76:9, and
E(DEb )~90:4; and the expected patient-years at risk are
E(TCa )~451:6,
E(TCb )~389:8,
E(TEa )~480:6,
and
E(TEb )~451:8. The numbers of subjects with both events with
the shared frailty are E(DCab )~67:4 and E(DEab )~51:6, and
those expected under independence (by chance) are
E(DCabI )~54:8 and E(DEabI )~36:3. These yield s2a ~7:76E–4,
PLOS ONE | www.plosone.org

the score vector for the ‘th subject and Ij (^
hj ) is the model based
estimate of the expected information for the jth outcome. Also, let
hj ) denote the Kj |N matrix where the ‘th column is the score
Uj (^
vector U ‘j (h^j ). Then the generalization of the information
sandwich robust estimate of the covariance matrix of the joint
h~(^
h’a ^
h’b )’ is provided by
set of estimates ^
"
ha )
SR (^
^
SR (h)~
^
SR (ha ,^
hb )

^b )
S R (^
ha ,h
^
SR (hb )

#
ð67Þ

where
SR (^
hj )~Ij (^
hj ){1 Uj (^
hj )Uj (^
hj )’Ij (^
hj ){1 ,

j~a,b

ð68Þ

ha ,^
hb )~Ia (^
ha ){1 Ua (^
ha )Ub (^
hb )’Ib (^
hb ){1 :
SR (^
The estimated variances of the group coefficients in the two
^2a ~SR (^
ha )1,1 and
models is then provided by the elements s
10
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^ 2b ~SR (^hb )1,1 , and the covariance by s
^ab ~SR (^ha ,^
s
hb )1,1 . The
scale-based test is then provided by (5) with (^ha1 ,^hb1 ) substituted
for (^da ,^db ). Alternately, Z-tests of the group effect in the two
models are then provided by Zj ~^hj1 =sj , j~a,b, and the
correlation
of
these
tests
by
^b ). This provides the ZCov(Za ,Zb )~Corr(^ha1 ,^hb1 )~^
sab =(^
sa s
based test as in (19).
Pipper et al. also describe the application of the joint models
where data for a subject is missing for one of the component
models (but not both). Under the assumption of missing
completely at random, then the score vector elements for that
subject are set to zero in the corresponding score matrix U.
It would be difficult to evaluate the sample size and power of
such a model-based test. However, simple computations such as
those herein could be applied, e.g. the power of a test for a
difference in means and proportions when the actual analysis will
employ a linear regression model and a logistic model.
Pipper et al. originally provided an R package multmod to fit
multiple models and to compute the covariances of the coefficients
in the models. That has since been replaced by the R package
multcomp.

Alternately, rather than use any cutpoints to construct derived
binary variables, an analysis could compare the groups with
respect to the six quantitative traits (including systolic and diastolic
blood pressure) simultaneously.
Table 1 presents a comparison of the lifestyle versus metformin
groups for each of the binary outcomes and each of the
corresponding quantitative outcomes. The overall prevalence of
the metabolic syndrome using the composite binary outcome does
not differ significantly between groups, although the prevalence is
about 2% lower in the lifestyle group.
For all variables other than HDL, higher values are worse, so
that a positive difference between metformin minus lifestyle
indicates a benefit for lifestyle. In order for the same to apply to
HDL, the analysis employed the negative values of HDL.
All p-values are one-sided. Some of the one-sided p-values are
.0.5 indicating a negative Z-value favoring metformin. However,
most of these differences are close to zero. For no measure is there
evidence that intensive lifestyle is worse than metformin, and all
significant differences favor the lifestyle group. Thus, these data
are consistent with the alternative hypothesis that lifestyle has a
beneficial effect on some of the outcomes, and no adverse effect for
any.
Table 2 presents the correlations among the measurements.
The modest to low correlations suggest that a multivariate test will
provide greater power than individual tests, especially when the
latter are adjusted for multiple tests.
Table 3 then presents the Wei-Lachin scale-based and Z-based
one-directional multivariate test Z and one-sided p-values for three
different analyses of these data. As would be expected, the analysis
of all six quantitative traits is more powerful or sensitive than the
analyses involving binary traits, with p-values ,0.001 using either
the scale or Z-based tests. The analysis of the 5 binary indicator
variables produces less significant results, and the scale-based test
for these data proves to be more powerful (larger Z-value) than the
Z-based test, although both are significant. An alternative would
be to conduct an analysis of the three binary traits defined from
multiple criteria (waist, HDL, hypertension) and the other two
quantitative traits (triglycerides and glucose). This yields results
intermediate to those of the analysis of all quantitative and all
binary traits.
Regardless of which of these options might have been chosen as
the basis for the analysis, all would have provided a statistically
significant result whereas the analysis of the composite metabolic
syndrome outcome failed to demonstrate a beneficial effect of
lifestyle versus metformin (Table 1, p = 0.22).

Example – The Diabetes Prevention Program
The Diabetes Prevention Program compared the risk of onset of
type 2 diabetes and deterioration of metabolic function among
participants randomly assigned to an intensive lifestyle intervention (ILS) versus treatment with the glucose lowering drug
metformin and versus a placebo control with no lifestyle
intervention [28]. The study showed that intensive lifestyle
provided a 58% reduction in diabetes risk versus placebo and
39% versus metformin, and that metformin produced a 31%
reduction versus placebo. The study also evaluated the differences
among treatments in the prevalence of developing the metabolic
syndrome, a metabolic state that is linked not only with risk of onset
of diabetes but also the risk of developing cardiovascular disease.
The prevalence of the metabolic syndrome is characterized by 3 or
more of the following 5 criteria: abdominal obesity defined as a
waist circumference .102 cm among men or .88 cm among
women, serum triglycerides (a bad cholesterol) $150 mg/dL,
HDL (a good cholesterol) ,40 mg/dL among men or ,50 mg/
dL among women, systolic/diastolic blood pressure $130/85 mm
Hg, and fasting glucose $110 mg/dL, the latter met by many of
the study subjects. [29]
Of the 3234 randomized, 1388 (43%) already met the metabolic
syndrome criteria. Among the remainder who were evaluated at 3
years of follow-up (i.e., free of the syndrome on entry), 22% (363 of
1673) had the syndrome present. [30] Herein we compare the
prevalence of the metabolic syndrome and its components at 3
years of follow-up among those in the lifestyle versus metformin
treated groups.
The classification of the metabolic syndrome is a composite
outcome, i.e. a single binary trait to designate that the criteria were
met. An alternative would be to construct an analysis of the 5
binary traits using the one-directional multivariate test described
herein.
For two of the traits (waist circumference and HDL) there are
separate criteria for men and women, and for hypertension both
systolic and diastolic blood pressure are employed, whereas for the
other two traits there is a single cutpoint for the corresponding
quantitative measure. Thus an alternate analysis would be to used
these three composite binary traits in conjunction with an analysis
of the other two quantitative variables (triglycerides and glucose).
PLOS ONE | www.plosone.org

Discussion
A number of multivariate one-directional or one-sided tests
have been described. Virtually all were developed to apply to a
multivariate test of the difference in means between two groups for
a multivariate outcome, such as repeated measures. These are also
described for the case of two measures with group differences ^
da
and ^
db as described above.
For a test based on multivariate normal observations, such as K
repeated measures, Kudo [31] described the multivariate onesided likelihood ratio test (LRT ) of the K-variate generalization of
the ordered hypotheses in (2) assuming that the covariance matrix
S is known, and Pearlman [32] described the LRT when the
estimated covariance matrix is employed. For the case of the two
statistics herein, Pearlman’s LRT is based on the statistic
SLR ~min½^
da _ 0), (^
db _ 0)~max½0, min(^
da ,^
db )
11
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Table 1. Differences between the DPP intensive lifestyle (ILS, n = 571) versus metformin (MET, n = 557) treated patients at three
years of follow-up with respect to quantitative trait components of the metabolic syndrome, and binary indicators of abnormal
levels, and the overall incidence of the metabolic syndrome among those free of the syndrome on entry.

Mean (SE)
Characteristic

ILS

%

p

MET

ILS

p

MET

Waist (cm)

97 (0.61)

99 (0.60)

0.0030

54.6

63.4

0.0015

Triglycerides (mg/dl)

115 (2.5)

125 (2.9)

0.0017

19.3

25.3

0.0074

HDL (mg/dl)

51.3 (0.53)

50.7 (0.53)

0.10

36.6

37.9

0.33

9.5

9.3

0.53

24.1

23.5

0.60

18.2

20.1

0.22

BP hypertension
Systolic (mm Hg)

120 (0.64)

122 (0.60)

0.0046

Diastolic (mm Hg)

74 (0.40)

76 (0.37)

0.0001

Glucose (mg/dL)

104 (0.49)

103 (0.53)

0.59

Metabolic Syndrome

Analysis restricted to those free of the metabolic syndrome at entry. One-sided p-values computed from a t-test for quantitative measures and chi-square test for binary
variables.
doi:10.1371/journal.pone.0108784.t001

However, this test has the unsavory feature that if either ^
d value
is negative, regardless how greatly so, the value is set to zero in the
~ a ~{1000
computation of the test statistic. Thus, for example if Z
~
and Zb ~10, then SALR ~10, and depending on the estimated
covariance values, could reject H0S in favor of H1S, even though it
is clear that H1S does not apply. In a recent overview, Tamhane
and Logan [36] have suggested that ‘‘If several endpoints show
moderate negative differences or even if a few show very large
negative differences, then these tests should not be used because
the a priori assumption of positive treatment effects in all
endpoints is questionable.’’ However, to apply this recommendation in practice violates the principle that the test statistic for a
study be specified a priori. In effect, the recommended practice
could be viewed as a two-stage inference process - first determine if
the differences are positive, and if so conduct the test. This would
clearly inflate the type I error probability.
Other tests have been proposed that are based in part on
Hotelling’s T2 statistic that is equivalent to the expression in (8)
and is distributed as T2 on K df under the assumption of
multivariate normality of the observations. Under this assumption,
T2 provides an optimal test of the null hypothesis against the global
alternative presented in (7). Follman [37] describes a test of H0
versus H1+: (da zdb )w0 that is not the same as H1S above. His
2
test rejects H0 in favor of H1+ if T2 is significant at level 2a and
Xz
db )w0. This test also could lead to rejection of H0 when
(^
da z^
either the true da or db is a large negative value and the other an
even larger positive value.

where ‘‘_’’ designates the maximum of the two quantities. Thus, if
either ^d is negative the resulting test statistic quantity is zero.
However, the distribution of SLR is computationally difficult and
the test is not convenient for practical use.
Tang, Gnecco and Geller [33] proposed a computationally
simpler approximation to the LRT. Their approximate or ALR
test is not an approximation in the sense, say, of a series expansion,
but rather is an approximation in the sense that the alternative
hypothesis parameter space is an approximation of that of the
LRT. Their statistic is of the form
~ a _ 0)z(Z
~ b _ 0)
SALR ~(Z

ð70Þ

~ b are uncorrelated standardized Z-statistics
~ a and Z
where Z
^ vector. Under the
obtained as linear transformations of the D
assumption that the covariance matrix is known, then
^ where A is a square matrix such that
~ Z
~a Z
~ b )’~A’D
Z~(
A’A~S{1 and A’SA~I, such as is obtained from a Choleski
decomposition. The distribution of this statistic is a simplified Chibar-squared distribution [34], though still requiring some computation to obtain a p-value. However, when an estimate of the
covariance matrix is employed to provide the A transformation
matrix, various authors have shown that the test can be serverely
liberal, i.e. has an inflated type I error probability. In this case,
Tamhane and Logan [35] described an accurate approximation to
the distribution of the resulting test using a mixture of Fdistributions, that also requires some computation to determine
levels of significance.

Table 2. Correlations among the component measurements obtained from the pooled within-groups covariance matrix.

Waist (cm)

Triglycerides

HDL

SBP

DBP

Glucose

0.07

0.24

0.13

0.19

0.28

0.27

0.03

0.11

0.06

20.09

0.04

0.14

0.55

0.08

Triglycerides (mg/dl)
HDL (mg/dl)
Systolic (mm Hg)
Diastolic (mm Hg)

0.05

doi:10.1371/journal.pone.0108784.t002
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Table 3. The Wei-Lachin scale-based and Z-based one-directional multivariate test Z and one-sided p-values for three different
analyses of the DPP metabolic syndrome data.

Z-based Test

Scale-based Test
Analysis

Zs

ps

ZS,z

pS,z

All quantitative (6)

3.52

0.00022

3.48

0.00025

All binary (5)

2.37

0.0089

2.22

0.0131

Mixed (5)

2.49

0.0064

2.02

0.0215

doi:10.1371/journal.pone.0108784.t003

the Wei-Lachin test as a trivial special case. Frick [42] also showed
that O’Brien’s OLS test is biased.
Thus, among the various tests that have been proposed that
could be applied to the assessment of simultaneous differences
between groups for multiple outcomes, the Wei-Lachin test has the
advantages that it is simple to compute; can be applied to mixtures
of outcomes on different scales (e.g. means and proportions); that it
has a large sample normal distribution (or a t-distribution with
normal errors); provides a test with type I error probabilities close
to the nominal levels with generally acceptable sample sizes; is
directed towards the specific multivariate one-directional alternative of interest, is maximin efficient relative to the possible true but
unknowable optimal test, and readily provides for the computation
of sample size and power.
Rahlfsand Vester [43] describe applications of the Wei-Lachin
test to the analysis of multiple outcomes using the multivariate
Mann-Whitney difference analysis described initially by Thall and
Lachin [11]. The authors are affiliated with idv Data Analysis and
Study Planning that also markets a program (TESTIMATE) that
conducts such Wei-Lachin analyses. Pan [44] also recently
presented a review of various procedures including the WeiLachin test (called the SUM test therein) and some of the above
referenced one-directional procedures and showed by simulation
that the Wei-Lachin test had good power when the outcomes
tended to jointly show beneficial effects.
Programs for computations herein are available from www.bsc.
gwu.edu. These include the coefficient vector L for use in (10)
when Frick’s condition does not apply, the simulation event time
model, and the Wei-Lachin multivariate rank test.

Bloch, Lai and Tubert-Bitter [38] describe another test
procedure which requires that T2 reach significance at level a
two-sided and that both individual one-sided t-tests of an
indifference hypothesis be significant at level a. The indifference
hypothesis is H0I: (0§da w{e) and (0§db w{e) for some small
positive value e, and the alternative hypothesis is H1S as in (2)
above so that the one-sided t-test is of the form
(^dj {e)
tj ~ qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ,
^ (^dj )
V

j~a,b:

ð71Þ

This test was later criticized by Pearlman and Wu [39] who
proposed use of the one-sided LRT of Pearlman [32] in lieu of T2,
among other improvements. The result of either test, however,
depends on the specification of the value e and thus the test may
not be uniformly acceptable.
Other tests have also been applied, although not specifically
designed to test H0 against the one-sided alternative H1S in (2).
O’Brien [13] proposed his ordinary least squares (OLS) and
weigthed least squares (WLS) tests of H0 versus the alternative
hypothesis of a common difference H1A: da ~db ~d=0. Thus the
alternative hypothesis consists of the line of equality other than the
origin. The one-sided version of this test will also be sensitive to
alternatives where da and db are of similar positive magnitude, but
will not be optimal against the general alternative H1S. Pocock,
Geller and Tsiatis [40] describe the application of these tests to the
analysis of multiple outcomes in clinical trials on different scales.
For a two group comparison of a vector of repeated measures,
under the usual normal errors assumptions O’Brien also suggested
that his statistics were distributed as t. However, the exact small
sample distribution with normal errors is not known and many
authors have shown that the resulting t-statistics have an inflated
type I error probability. For a vector of repeated measures in two
groups, Läuter [41] shows that statistics that employ weighted
averages, as in O’Brien’s WLS test, are indeed distributed as t
provided that the weights are functions of the empirical covariance
matrix estimated from all groups combined rather than the pooled
within-groups covariance matrix estimate as employed by
O’Brien. He proposes a family of such weighted tests that includes
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